Journal of Endocrinological Investigation

, Volume 15, Issue 7, pp 507–512 | Cite as

Sodium ipodate increases triiodothyronine action in vivo

  • J. H. Hays
  • C. Eil
  • R. C. Smallridge


Sodium ipodate (IPO) has been shown to bind nuclear T3 receptors (NT3R) in vitro, but previous studies have conflicted in regard to demonstration of this interaction in vivo. We sought evidence for IPO-NT3R binding in vivo by giving large doses of IPO to thyroidectomized (TDX) rats replaced with low doses of T3. We predicted that IPO-NT3R binding would inhibit T3 induced increases in mitochondrial alpha glycerophosphate dehydrogenase activity (alpha-GPDH) in kidney, heart and liver. Three groups of ten euthyroid rats each received 13 daily injections of vehicle, or 6 or 12 mg/100 g body weight of IPO, respectively. Both doses of IPO resulted in decreases in serum T3 and increases in serum TSH. Liver and kidney alpha-GPDH, however, were decreased only in the group receiving 6 mg IPO. In addition, three groups of 30 TDX rats were implanted with osmotic minipumps that contained T3 in the following concentrations: 33, 69 and 96 ng/ul. Ten rats in each group received 13 daily injections of vehicle, or IPO (vide supra). The alpha-GPDH responses were complex in that there was significant interaction between T3 and IPO effects in the kidney (A×B F ratio 5.13, p<0.001) and liver (A×B F ratio 2.85, p<0.05). The major finding, however, was that alpha-GPDH was not significantly reduced by IPO in any T3 replaced group. Rather, in all three organs, alpha GPDH was significantly increased above that produced by T3 alone by at least one combination of IPO and T3. Changes in serum TSH also suggested that IPO could enhance T3 effects. We conclude that IPO-NT3R binding is not a prominent mechanism via which the drug attenuates T3 effects in vivo. The data suggest that IPO may enhance T3 effects at the cellular level and that this enhancement may not be reflected by routinely monitored serum TSH. The latter observation may have clinical importance.


Sodium ipodate alpha glycerophosphate dehydrogenase activity in vivo 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Eil C., Chestnut R.Y. The effects of radiographic contrast agents and other compounds on the nuclear binding of L-[125|] triiodothyronine in dispersed human fibroblasts. J. Clin. Endocrinol. Metab. 60: 548, 1985.PubMedCrossRefGoogle Scholar
  2. 2.
    DeGroot L.J., Rue P.A. Roentgenographic contrast agents inhibit triiodothyronine binding to nuclear receptors in vitro. J. Clin. Endocrinol. Metab. 49: 538, 1979.PubMedCrossRefGoogle Scholar
  3. 3.
    Burman K.D., Lukes Y.G., Latham K.R., Wartofsky L. Ipodate and 8-anilino-1-naphthalene sulfonic acid block receptor binding of T-3 in rat liver. Horm. Metab. Res. 12: 685, 1980.PubMedCrossRefGoogle Scholar
  4. 4.
    Kaplan M.M., Utiger R.D. lodothyronine metabolism in rat liver homogenates. J.Clin. Invest. 61: 459, 1978.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Chopra I.J., Huang T-S., Hurd R.E., Solomon D.H. A study of cardiac effects of thyroid hormones: evidence for amelioration of the effects of thyroxine by sodium ipodate. Endocrinology 114: 2039, 1984.PubMedCrossRefGoogle Scholar
  6. 6.
    Melmed S., Melson M., Kaplowitz N., Yamada T., Hershman J.M. Glutathione dependent thyroxine 5′-monodeiodination modulates growth hormone production by cultured nonthyrotropic rat pituitary cells. Endocrinology 108: 970, 1981.PubMedCrossRefGoogle Scholar
  7. 7.
    DeVito W.J., Connors J.M., Hedge G.A. The pituitary TSH response to TRH is inversely related to the plasma TSH concentration and directly related to the pituitary TSH content during hypothyroidism in the rat. Acta Endocrinol. (Copenh.) 114: 27, 1987.Google Scholar
  8. 8.
    Lee Y-P., Lardy H.A. Influence of thyroid hormones of L-alpha-glycerophosphate dehydrogenase and other dehydrogenases in various organs of the rat. J. Biol. Chem. 240: 1427, 1965.PubMedGoogle Scholar
  9. 9.
    Smallridge R.C., Rogers J., Verma P.S. Serum angiotensin converting enzyme: alterations in hyperthyroidism, hypothyroidism and subacute thyroiditis. JAMA 250: 2489, 1983.PubMedCrossRefGoogle Scholar
  10. 10.
    Rohrbach M.S. [Glycine-1-14C] Hippuryl-L-histidyl-1 leucine: a substrate for the radiochemical assay of angiotensin converting enzyme. Anal. Biochem. 84: 272, 1978.PubMedCrossRefGoogle Scholar
  11. 11.
    Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265, 1951.PubMedGoogle Scholar
  12. 12.
    Smallridge R.C., Verma P.S. Angiotensin-converting enzyme activity is altered in the hypothyroid rat. 7th International Congress of Endocrinology, Excerpta Medica: International Congress Series 652, 1984, p. 1489 (abstract).Google Scholar
  13. 13.
    Wu S-Y., Chopra I.J., Solomon D.H., Johnson D.E. The effect of repeated administration of ipodate (Oragrafin) in hyperthyroidism. J. Clin. Endocrinol. Metab. 47: 1358, 1978.PubMedCrossRefGoogle Scholar
  14. 14.
    Lim V.S., Zavala D.C., Flanigan M.J., Freeman R.M. Blunted peripheral tissue responsiveness to thyroid hormone in uremic patients. Kidney Int. 31: 808, 1987.PubMedCrossRefGoogle Scholar
  15. 15.
    Sogol P.B., Hershman J.M., Reed A.W., Dillmann W.H. The effects of amiodarone on serum thyroid hormones and hepatic thyroxine 5′-monodeiodination in rats. Endocrinology 113: 1464, 1983.PubMedCrossRefGoogle Scholar
  16. 16.
    Felicetta J.V., Bagchi N., Brown T.R., Czanko R. Amiodarone and ipodate reduce hepatic levels of thyroid-sensitive enzymes. Clin. Res. 34: 908A, 1986.Google Scholar
  17. 17.
    Chopra I.J., Solomon D.H., Chopra U., Wu S.Y., Fisher D.A., Nakamura Y. Pathways of metabolism of thyroid hormones. Recent. Prog. Horm. Res. 34: 521, 1978.PubMedGoogle Scholar
  18. 18.
    Obregon M.J., Pascual A., Mallol J., Morreale de Escobar G., Escobar del Rey F. Evidence against a major role of L-thyroxine at the pituitary level: Studies in rats treated with iopanoic acid (Telepaque). Endocrinology 106: 1827, 1980.PubMedCrossRefGoogle Scholar
  19. 19.
    Pascual A., Montiel F., Aranda A. Effects of iopanoic acid on thyroid hormone receptor, growth hormone production, and triiodothyronine generation from thyroxine in pituitary GH1 cells. Endocrinology 120: 1089, 1987.PubMedCrossRefGoogle Scholar
  20. 20.
    Felicetta J.V., Czanko R., Huber-Smith M.J., McCann D.S. Cholecystographic agents and sulfobromophthalein inhibit the binding of L-thyroxine to plasma membranes of rat hepatocytes. Endocrinology 118: 2500, 1986.PubMedCrossRefGoogle Scholar
  21. 21.
    Silva J.E., Larsen P.R. Contributions of plasma triiodothyronine and local thyroxine monodeiodination to triiodothyronine to nuclear triiodothyronine receptor saturation in pituitary, liver and kidney of hypothyroid rats. J. Clin. Invest. 61: 1247, 1978.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Van Doorn J., Roelfsema F., Van Der Heide D. Concentrations of thyroxine and 3, 5, 3′ — triiodothyronine at 34 different sites in euthyroid rats as determined by isotopic equilibrium technique. Endocrinology 117: 1201, 1985.PubMedCrossRefGoogle Scholar
  23. 23.
    Caldwell G., Errington M., Toft A.D. Resistant hyperthyroidism induced by sodium ipodate used as treatment for Graves’ disease. Acta Endocrinol. (Copenh.) 120: 215, 1989.Google Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1992

Authors and Affiliations

  • J. H. Hays
    • 1
  • C. Eil
    • 1
  • R. C. Smallridge
    • 1
  1. 1.Clinical Physiology Branch, Division of MedicineWalter Reed Army Institute of ResearchWashington, D.C.USA

Personalised recommendations